Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Structural Heart Disease
How should one approach management of a patient with asymptomatic severe primary (prolapse) TR and normal RV function (EF and strain) but with RA/RV enlargement?
Related Questions
Are there instances where TAVR should be considered for patients with moderate AS and HFrEF?
What would be your approach for the management of asymptomatic, severe AS with a peak velocity of 5 m/s in an otherwise physically active patient in their mid-90s without significant co-morbidities?
How do you decide between opting for semi-elective outpatient versus inpatient TAVR for patients with severe critical AS?
Would it be reasonable to consider combined BAV plus staged PCI in a patient presenting with ACS and new LV systolic dysfunction, moderate aortic stenosis, and complex bifurcating left main disease and RCA CTO?
How would you approach the INR goal in a patient with mechanical aortic valve and high bleeding risk factors like immune thrombocytopenia, AV malformations and recurrent GI bleeds, etc.?
Is there any role for routine CT TAVR a few months after TAVR to look for HALT?
In a patient with suspected prosthetic valve endocarditis, how long after prosthetic valve implantation is an FDG PET reasonable to rule out infection?
Are there any trans-cathter options available in a patient s/p m-TEER with residual severe MR with high surgical risk who has worsening heart failure symptoms?
In patients with moderate calcific mitral stenosis, possible HFpEF and dyspnea on exertion, how would you differentiate the etiology of the symptoms?
Are there specific types of bioprosthetic valves that would make you inclined to choose VKA in lieu of a DOAC for systemic anticoagulation several months post-valve replacement?
